乐虎lehu国际官网

Analysis of the efficacy of polymyxin B and recombinant human epidermal growth factor in the combined treatment of infected wounds in burn patients

2025-09-06 0

Abstract:Objective To evaluate the clinical effect of the combination of polymyxin B and recombinant human epidermal growth factor in the treatment of infected wounds in patients with burns, in order to guide clinical diagnosis and treatment. Methods 50 cases of deep Ⅱ degree burns patients who attended the burns department of the hospital from January 2014 to June 2015 were selected as the research objects, and were divided into control group and observation group according to the randomized numerical table method, each group had 25 cases, the observation group was given the combined treatment of polymyxin B and recombinant human epidermal growth factor, and the control group was given the treatment of recombinant human epidermal growth factor, and the clinical therapeutic effect of the patients in the two groups was compared with each other using The data were statistically analyzed by SPSS 17.0 software. Results of the observation group granulation tissue growth time was (5.3±1.3)d, compared with the control group (6.9±1.7)d, the difference was statistically significant (P<0.05); observation group patients with a scar incidence rate of 12.0%, the control group was 16.0%, the difference between the two groups is not statistically significant; observation group patients with a wound healing rate of 7, 14, 21d were 44.0%, 64.0%, 92.0% and 44.0% respectively, 64.0%, 92.0% in the observation group and 16.0%, 32.0% and 60.0% in the control group respectively, and the differences between the two groups were statistically significant (P<0.05); the infection rates of 7, 14 and 21d wounds in the patients of the observation group were 64.0%, 52.0%, and 28.0% respectively, and those of the patients of the control group were 88.0%, 80.0%, and 68.0%, and the differences between the two groups were statistically significant (P<0.05). The differences were statistically significant (P<0.05). Conclusion: The combination of polymyxin B and recombinant human epidermal growth factor in the treatment of infected wounds in burn patients has the advantages of preventing infection, rapid healing and low incidence of scarring, which is worthy of clinical promotion.


 LIU Jun, LI Wuquan, HAN Yalong, JI Gang, RIVER. Analysis of the efficacy of polymyxin B and recombinant human epidermal growth factor in the combined treatment of infected wounds in burn patients[J]. Chinese Journal of Hospital Infection, 2016, 26 (04): 886-888. 

To Top